Absci Corporation develops generative AI-designed biologic therapeutics as a clinical-stage biopharmaceutical company. News about ABSI centers on its Integrated Drug Creation platform, internal prolactin and prolactin receptor (PRLR) programs, and clinical development of ABS-201, an anti-PRLR antibody being developed for androgenetic alopecia and endometriosis.
Recurring updates cover HEADLINE trial safety, tolerability and pharmacokinetic disclosures, preclinical pipeline additions such as ABS-202, business and operating results, clinical advisory activity, healthcare conference participation, executive leadership changes, and Nasdaq inducement equity grants.
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on AI-driven therapeutic development, has announced its participation in three major upcoming investor conferences in September 2025.
The company will attend the 2025 Wells Fargo Healthcare Conference in Boston for one-on-one meetings on September 3, the Morgan Stanley 23rd Annual Global Healthcare Conference in New York for a fireside chat on September 8, and the H.C. Wainwright 27th Annual Global Investment Conference in New York for a fireside chat on September 9. Webcasts for the Morgan Stanley and H.C. Wainwright sessions will be available on Absci's investor relations website.
Absci Corporation (Nasdaq: ABSI) reported Q2 2025 financial results and business updates, highlighting significant developments in their clinical pipeline and financial position. The company successfully raised $64 million in gross proceeds in July 2025, extending their operational runway into H1 2028.
Key pipeline updates include the advancement of ABS-101 through clinical trials with an interim readout expected in H2 2025, and ABS-201 targeting Phase 1/2a initiation in early 2026. The company expanded its collaboration with Almirall, adding a second target for dermatological indications with potential milestone payments of up to $650 million.
Q2 2025 financial results showed revenue of $0.6 million (down from $1.3M in Q2 2024) and a net loss of $30.6 million (increased from $24.8M in Q2 2024). R&D expenses increased to $20.5 million, while SG&A expenses decreased to $8.5 million.
Absci (NASDAQ:ABSI) and Almirall (BME:ALM) have expanded their AI Drug Discovery collaboration by adding a second dermatology target. This expansion follows successful delivery of AI-designed antibody leads against the first difficult-to-drug target from their November 2023 collaboration.
The partnership combines Absci's Integrated Drug Creation™ platform with Almirall's dermatology expertise to develop novel therapeutics for skin diseases. Absci could receive up to $650 million in various milestone payments plus royalties, while being responsible for designing and validating therapeutic candidates. Almirall will lead preclinical and clinical development programs.
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on generative design for therapeutics, has scheduled its Q2 2025 earnings report and business update for August 12, 2025, after market close.
The company will host a conference call at 4:30 PM ET to discuss business developments, financial results, and future outlook. Investors can access the live webcast through Absci's investor relations website, with a replay available after the event.
Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company focused on AI-designed therapeutics, has announced the pricing of its public offering of 16,670,000 common stock shares at $3.00 per share. The offering is expected to generate gross proceeds of approximately $50 million before deductions.
The company has granted underwriters a 30-day option to purchase up to 2,500,500 additional shares. The proceeds will fund internal program advancement, investment in their Integrated Drug Creation™ platform, and general corporate purposes. The offering, managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen, is expected to close around July 25, 2025.
Absci (NASDAQ: ABSI), a clinical-stage biopharmaceutical company leveraging generative AI for therapeutic development, has announced a proposed public offering of $50 million in common stock. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million in shares.
The offering will be managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities as joint book-running managers. Proceeds will support Absci's internal program development, platform investment, and general corporate purposes. The offering will be made through an effective shelf registration statement previously filed with the SEC.
Absci (NASDAQ: ABSI) has appointed Mary Szela, a veteran biopharmaceutical executive, to its Board of Directors. Szela, currently CEO of TriSalus Life Sciences, brings over three decades of experience, notably leading the global launch and expansion of Humira® at Abbott Laboratories.
Szela joins Absci as the company advances its AI-designed biologics pipeline, including ABS-101, an anti-TL1A antibody for IBD with Phase 1 data expected in 2025, and ABS-201 for androgenetic alopecia planned for clinical trials in early 2026. Her board experience includes Prometheus Biosciences (acquired by Merck for $10.8B), Kura Oncology, and Novo Nordisk.
Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company focused on generative design for therapeutics, has announced its participation in four major upcoming investor conferences in June 2025:
- Jefferies Global Healthcare Conference in New York on June 5 at 2:00 PM ET
- Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9 at 8:40 AM ET
- TD Cowen 4th Annual Tools/Dx Revolution in Dana Point from June 22-25
- Morgan Stanley 4th Annual Life Sciences Data and AI Conference in New York on June 24
Live and archived webcasts for the Jefferies and Goldman Sachs presentations will be available on Absci's investor relations website.
Absci Corporation (NASDAQ: ABSI) has initiated its first Phase 1 clinical trial for ABS-101, an AI-designed anti-TL1A antibody for treating Inflammatory Bowel Disease (IBD). The trial marks Absci's transition to a clinical-stage company and will evaluate the first AI-designed biologic for IBD. The randomized, double-blind, placebo-controlled study will enroll approximately 40 healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics.
ABS-101 is designed for quarterly subcutaneous dosing and demonstrates superior potency against monomeric and trimeric TL1A with reduced immunogenicity risk. Interim data is expected in the second half of 2025. Additionally, Absci is advancing ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with Phase 1 trials planned for early 2026.